Casgevy 2023 (FDA) sickle-cell + β-thalassemia first-approved CRISPR therapy. Vertex-CRISPR + bluebird Skysona / Zynteglo. ~$2-3M/treatment. Cross-listed L3 synthetic-biology CRISPR.
Casgevy 2023 (FDA) sickle-cell + β-thalassemia first-approved CRISPR therapy. Vertex-CRISPR + bluebird Skysona / Zynteglo. ~$2-3M/treatment. Cross-listed L3 synthetic-biology CRISPR.